Functional Roles of DYRK2 As a Tumor Regulator

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2023 Oct 27

PMID 37886981

Authors

Yuta Mochimaru

Kiyotsugu Yoshida

Affiliations

Soon will be listed here.

Abstract

The dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) regulates the induction of apoptosis and DNA repair, metastasis inhibition, cell cycle G1/S transition, protein scaffold stability for E3 ligase complexes, and embryogenesis. Owing to these functions, DYRK2 is thought to regulate tumorigenesis, and its function in cancer has been investigated. Notably, DYRK2 has been reported to function as a tumor suppressor; however, it has also been reported to act as an oncogene in some cancers. This discrepancy makes it difficult to elucidate the conserved functions of DYRK2 in cancer. Here, we reviewed the functions of DYRK2 in various cancers. Patient tissue samples were evaluated for each cancer type. Although some studies have used cell lines and/or xenografts to elucidate the mechanism of DYRK2 function, these studies are not sufficient to understand the role of DYRK2 in cancers. In particular, studies using genetically modified mice would help us to understand the reported functional duality of DYRK2 in cancer.

Citing Articles

DYRK2 controls GSTPI expression through ubiquitination and degradation of Twist1 to reduce chemotherapy resistance caused by EMT in breast cancer.

Xu G, Zhou M, Li Q, Li Y, Zhang C, Yang Z J Mol Histol. 2024; 56(1):35.

PMID: 39641870 DOI: 10.1007/s10735-024-10300-7.

References

Yamashita S, Chujo M, Tokuishi K, Anami K, Miyawaki M, Yamamoto S . Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2009; 138(6):1303-8. DOI: 10.1016/j.jtcvs.2009.08.003. View

Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T . Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2007; 26(1):101-6. DOI: 10.1038/nbt1374. View

Wu C, Sun G, Wang F, Chen J, Zhan F, Lian X . DYRK2 downregulation in colorectal cancer leads to epithelial-mesenchymal transition induction and chemoresistance. Sci Rep. 2022; 12(1):22496. PMC: 9797492. DOI: 10.1038/s41598-022-25053-0. View

Ito D, Yogosawa S, Mimoto R, Hirooka S, Horiuchi T, Eto K . Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer. Cancer Sci. 2017; 108(8):1565-1573. PMC: 5543514. DOI: 10.1111/cas.13280. View

Jung H, Wang X, Jun S, Park J . Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation. J Biol Chem. 2013; 288(10):7252-62. PMC: 3591633. DOI: 10.1074/jbc.M112.416792. View

Becker W . Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control. Cell Cycle. 2012; 11(18):3389-94. PMC: 3466549. DOI: 10.4161/cc.21404. View

Lara-Chica M, Correa-Saez A, Jimenez-Izquierdo R, Garrido-Rodriguez M, Ponce F, Moreno R . A novel CDC25A/DYRK2 regulatory switch modulates cell cycle and survival. Cell Death Differ. 2021; 29(1):105-117. PMC: 8738746. DOI: 10.1038/s41418-021-00845-5. View

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

Tandon V, Moreno R, Allmeroth K, Quinn J, Wiley S, Nicely L . Dual inhibition of HSF1 and DYRK2 impedes cancer progression. Biosci Rep. 2023; 43(1). PMC: 9894012. DOI: 10.1042/BSR20222102. View

10.

Mimoto R, Taira N, Takahashi H, Yamaguchi T, Okabe M, Uchida K . DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail. Cancer Lett. 2013; 339(2):214-25. DOI: 10.1016/j.canlet.2013.06.005. View

11.

Santos-Duran G, Barreiro-Iglesias A . Roles of dual specificity tyrosine-phosphorylation-regulated kinase 2 in nervous system development and disease. Front Neurosci. 2022; 16:994256. PMC: 9492948. DOI: 10.3389/fnins.2022.994256. View

12.

Ryu K, Park S, Park S, Kim I, Han H, Kim H . p38 Stabilizes Snail by Suppressing DYRK2-Mediated Phosphorylation That Is Required for GSK3β-βTrCP-Induced Snail Degradation. Cancer Res. 2019; 79(16):4135-4148. DOI: 10.1158/0008-5472.CAN-19-0049. View

13.

Rowland B, Bernards R, Peeper D . The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol. 2005; 7(11):1074-82. DOI: 10.1038/ncb1314. View

14.

Koike C, Okudela K, Matsumura M, Mitsui H, Suzuki T, Arai H . Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma. Histol Histopathol. 2020; 36(3):305-315. DOI: 10.14670/HH-18-294. View

15.

Correa-Saez A, Jimenez-Izquierdo R, Garrido-Rodriguez M, Morrugares R, Munoz E, Calzado M . Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases. Cell Mol Life Sci. 2020; 77(23):4747-4763. PMC: 7658070. DOI: 10.1007/s00018-020-03556-1. View

16.

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

17.

Miller C, Aggarwal S, Lin T, Dagenais S, Contreras J, Orringer M . Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res. 2003; 63(14):4136-43. View

18.

Meulmeester E, Jochemsen A . p53: a guide to apoptosis. Curr Cancer Drug Targets. 2008; 8(2):87-97. DOI: 10.2174/156800908783769337. View

19.

Tanaka M, Yamashita S, Yoshinaga Y, Enomoto Y, Nohara Y, Ono S . Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence. Anticancer Res. 2022; 42(4):2079-2085. DOI: 10.21873/anticanres.15689. View

20.

Park C, Lacorazza H . DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells. Exp Mol Med. 2020; 52(10):1663-1672. PMC: 8080801. DOI: 10.1038/s12276-020-00515-5. View